Harbouring in the brain: A focus on immune evasion mechanisms and their deleterious effects in malaria and human African trypanosomiasis.

Malaria and human African trypanosomiasis represent the two major tropical vector-transmitted protozoan infections, displaying different prevalence and epidemiological patterns. Death occurs mainly due to neurological complications which are initiated at the blood-brain barrier level. Adapted host-immune responses present differences but also similarities in blood-brain barrier/parasite interactions for these diseases: these are the focus of this review. We describe and compare parasite evasion mechanisms, the initiating mechanisms of central nervous system pathology and major clinical and neuropathological features. Finally, we highlight the common immune mediated mechanisms leading to brain involvement. In both diseases neurological damage is caused mainly by cytokines (interferon-gamma, tumour necrosis factor-alpha and IL-10), nitric oxide and endothelial cell apoptosis. Such a comparative analysis is expected to be useful in the comprehension of disease mechanisms, which may in turn have implications for treatment strategies.

[The use of dried blood spots for HIV-antibody testing in Sahel]. / Dépistage du VIH en zone sahélienne a partir de sang séché sur sérobuvard.

Undertaking a HIV seroepidemiological survey in Sahel is logistically problematic, since countries like Niger or Mali are very large with scattered populations and harsh climatic conditions. Therefore, the replacement of serum samples by whole blood dried on filter papers has been studied for HIV-antibody testing with commercial kits that are commonly used. In Niger, two tests ELISA (Genscreen HIV1/2 version 2, Vironostika HIV Uni-Form II Ag/Ab) and two rapid tests (Determine HIV1/2 et Immunocomb II HIV1&2 Bispot) were used to compare the dried blood spots and serum samples from 43 control individuals. Both ELISAs gave an excellent correlation (r = 0.99 et r = 0.98) between the dried blood spots and serum absorbance values. Using the rapid tests, the HIV status was found 100% concordant with dried blood spots and serum samples. An algorithm using three out of the four mentioned tests was defined then validated on the dried blood spots of 163 control individuals (100% concordant). In conclusion, dried blood spots may accurately and profitably replace serum samples for the serodiagnosis of HIV infection and for mass serosurveys in Sahel.

Nationwide HIV prevalence survey in general population in Niger.

A national population-based survey was carried out in Niger in 2002 to assess HIV prevalence in the population aged 15-49 years. A two-stage cluster sampling was used and the blood specimens were collected on filter paper and tested according to an algorithm involving up to three diagnostic tests whenever appropriate. Testing was unlinked and anonymous. The refusal rate was 1.1% and 6056 blood samples were available for analysis. The adjusted prevalence of HIV was 0.87% (95% CI, 0.5-1.3%) and the 95% CI of the estimated number of infected individuals was 22 864-59 640. HIV-1 and HIV-2 represented, respectively, 95.6% and 2.9% of infections while dual infections represented 1.5%. HIV positivity rate was 1.0% in women and 0.7% in men. It was significantly higher among urban populations than among rural ones (respectively, 2.1% and 0.6%, P < 10(-6)). Using logistic regression, the variables significantly related to the risk of being tested positive for HIV were urban housing, increasing age and being either widowed or divorced. The estimate from the national survey was lower than the prevalence assessed from antenatal clinic data (2.8% in 2001). In the future, the representativeness of sentinel sites should be improved by increasing the representation of rural areas accounting for more than 80% of the population. Compared with other sub-Saharan countries, the HIV prevalence in Niger is still moderate. This situation represents a strong argument for enhancing prevention programmes and makes realistic the projects promoting an access to potent antiretroviral therapies for the majority.